131 related articles for article (PubMed ID: 18058835)
1. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice.
Sukel MP; Breekveldt-Postma NS; Erkens JA; van der Linden PD; Beiderbeck AB; Coebergh JW; Herings RM
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):125-34. PubMed ID: 18058835
[TBL] [Abstract][Full Text] [Related]
2. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
[TBL] [Abstract][Full Text] [Related]
3. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
4. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
5. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
Hooning MJ; Botma A; Aleman BM; Baaijens MH; Bartelink H; Klijn JG; Taylor CW; van Leeuwen FE
J Natl Cancer Inst; 2007 Mar; 99(5):365-75. PubMed ID: 17341728
[TBL] [Abstract][Full Text] [Related]
6. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Breast Cancer Res Treat; 2012 Sep; 135(2):335-46. PubMed ID: 22689092
[TBL] [Abstract][Full Text] [Related]
7. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
8. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
10. Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?
Davidson A; Gelmon K
Future Oncol; 2011 Jan; 7(1):37-55. PubMed ID: 21174537
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
12. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
13. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
[TBL] [Abstract][Full Text] [Related]
14. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.
van Nimwegen FA; Schaapveld M; Janus CP; Krol AD; Petersen EJ; Raemaekers JM; Kok WE; Aleman BM; van Leeuwen FE
JAMA Intern Med; 2015 Jun; 175(6):1007-17. PubMed ID: 25915855
[TBL] [Abstract][Full Text] [Related]
16. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.
Seicean S; Seicean A; Plana JC; Budd GT; Marwick TH
J Am Coll Cardiol; 2012 Dec; 60(23):2384-90. PubMed ID: 23141499
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
18. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
Nolan L; Darby A; Boleti K; Simmonds P
Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy.
Yood MU; Wells KE; Alford SH; Dakki H; Beiderbeck AB; Hurria A; Gross CP; Oliveria SA
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):818-27. PubMed ID: 22419528
[TBL] [Abstract][Full Text] [Related]
20. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
